zur Navigation zum Inhalt


VIDEO: Weniger herumreden und mehr Hinwendung

02/2017 Gesprächsführung. Moderne Krebstherapien ermöglichen Patienten mit fortgeschrittenen Karzinomen eine längere Lebenserwartung. Dadurch werden Ärzte in der Kommunikation mit den Betroffenen mit Situationen konfrontiert, für die sie nicht entsprechend ausgebildet wurden. [...]


01/2017 Dear Colleagues,

From 4th to 7th December, 2016, the IASLC 17th World Conference on Lung Cancer (WCLC) took place in Vienna, Austria, attracting more than 6,500 participants from 93 countries. Scientific insights presented at the IASLC WCLC 2016 are summarised in this memo inOncology congress report that covers a range of topics relating to the diagnosis and treatment of lung [...]

Emerging treatments in ALK-positive NSCLC: new options, but also new challenges

01/2017 | 15 Kommentare
Treatment with the ALK tyrosine kinase inhibitor (TKI) crizotinib has been established as a standard first-line option in patients with _ALK_-rearranged advanced NSCLC. Before the advent of crizotinib, a platinum–pemetrexed doublet followed by pemetrexed maintenance was standard of care in non-squamous NSCLC. [...]

Notable advances in the field of anti-EGFR therapy

01/2017 The irreversible ErbB family blocker afatinib and the reversible EGFR TKIs gefitinib and erlotinib have been approved as first-line therapies for treatment of NSCLC patients with _EGFR_-sensitising mutations. However, resistance frequently develops, which indicates the need for new agents. [...]

Inhibition of HER2 driver mutations can confer benefits

01/2017 Amplification or overexpression of _HER2_ (_ErbB2_) has been identified in NSCLC, and somatic _HER2_ mutations occur in approximately 2 % to 4 % of patients [1, 2]. Response to chemotherapy is poor in the setting of _HER2_-mutant advanced NSCLC [3]. [...]

Practice-changing refinements of lung cancer staging

01/2017 The 8th edition of the TNM classification has recently come into effect. Compared to the 7th edition published in 2009 [1], several important adjustments have been made to lung cancer staging with the aim of improving prognostication and research [2]. [...]

Medizin heute

Aktuelle Printausgaben